[go: up one dir, main page]

TW200519092A - Malonamide derivatives - Google Patents

Malonamide derivatives

Info

Publication number
TW200519092A
TW200519092A TW093126876A TW93126876A TW200519092A TW 200519092 A TW200519092 A TW 200519092A TW 093126876 A TW093126876 A TW 093126876A TW 93126876 A TW93126876 A TW 93126876A TW 200519092 A TW200519092 A TW 200519092A
Authority
TW
Taiwan
Prior art keywords
lower alkyl
halogen
hydrogen
cycloalkyl
phenyl
Prior art date
Application number
TW093126876A
Other languages
English (en)
Inventor
Alexander Flohr
Guido Galley
Roland Jakob-Roetne
Eric Argirios Kitas
Jens-Uwe Peters
Wolfgang Wostl
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of TW200519092A publication Critical patent/TW200519092A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/18Dibenzazepines; Hydrogenated dibenzazepines
    • C07D223/20Dibenz [b, e] azepines; Hydrogenated dibenz [b, e] azepines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/141,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/161,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/181,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D313/00Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02Seven-membered rings
    • C07D313/06Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/10Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D313/14[b,f]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
TW093126876A 2003-09-09 2004-09-06 Malonamide derivatives TW200519092A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03019683 2003-09-09

Publications (1)

Publication Number Publication Date
TW200519092A true TW200519092A (en) 2005-06-16

Family

ID=34224068

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093126876A TW200519092A (en) 2003-09-09 2004-09-06 Malonamide derivatives

Country Status (34)

Country Link
US (1) US7160875B2 (zh)
EP (1) EP1711470B1 (zh)
JP (2) JP4571639B2 (zh)
KR (3) KR20070087233A (zh)
CN (1) CN100593539C (zh)
AR (1) AR045609A1 (zh)
AT (1) ATE428698T1 (zh)
AU (1) AU2004270361B2 (zh)
BR (1) BRPI0413533A (zh)
CA (1) CA2537440C (zh)
CO (1) CO5660268A2 (zh)
CR (1) CR8264A (zh)
CY (1) CY1109225T1 (zh)
DE (1) DE602004020680D1 (zh)
DK (1) DK1711470T3 (zh)
EA (1) EA009940B1 (zh)
EC (1) ECSP066414A (zh)
ES (1) ES2322652T3 (zh)
HR (1) HRP20090266T1 (zh)
IL (1) IL173905A (zh)
MA (1) MA28034A1 (zh)
MX (1) MXPA06002562A (zh)
MY (1) MY141308A (zh)
NO (1) NO20061047L (zh)
NZ (1) NZ545538A (zh)
PL (1) PL1711470T3 (zh)
PT (1) PT1711470E (zh)
RS (1) RS20060146A (zh)
SI (1) SI1711470T1 (zh)
TN (1) TNSN06077A1 (zh)
TW (1) TW200519092A (zh)
UA (1) UA83501C2 (zh)
WO (1) WO2005023772A1 (zh)
ZA (1) ZA200601989B (zh)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008172A (es) * 2003-02-04 2005-10-05 Hoffmann La Roche Derivados de malonamida como inhibidores gamma-secretasa.
ES2322652T3 (es) * 2003-09-09 2009-06-24 F. Hoffmann-La Roche Ag Derivados de malonamida bloqueantes de la actividad gamma-secretasa.
MXPA06003870A (es) * 2003-10-06 2006-07-03 Hoffmann La Roche Derivados de dibenzo-azepina y benzo-diazepina substituidas utiles como inhibidores de gama-secretasa.
US7211573B2 (en) * 2004-12-08 2007-05-01 Hoffmann-La Roche Inc. Malonamide derivatives
EP2018368B1 (en) * 2006-03-27 2012-12-05 F. Hoffmann-La Roche AG Malonamide derivatives as gamma secretase inhibitors
MX2009002538A (es) * 2006-09-20 2009-03-20 Hoffmann La Roche Derivados de 4-oxo-2,3,4,5-tetrahidro-benzo[b][1,4]diazepina.
AU2008209861B2 (en) 2007-02-02 2012-08-09 F. Hoffmann-La Roche Ag 6-oxo-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl derivatives
WO2008110488A1 (en) * 2007-03-15 2008-09-18 F. Hoffmann-La Roche Ag Malonamides as orexin antagonists
US7579464B2 (en) * 2007-05-25 2009-08-25 Hoffmann-La Roche Inc. Process for preparation of enantiomerically pure compounds
US8741889B2 (en) 2008-01-11 2014-06-03 Hoffmann-La Roche Inc Method of treating non-small cell lung cancer and colon cancer with gamma-secretase inhibitor
KR20140007979A (ko) * 2008-01-11 2014-01-20 에프. 호프만-라 로슈 아게 암 치료를 위한 감마-세크레타제 저해제의 용도
US8309299B2 (en) 2010-05-19 2012-11-13 Hoffmann-La Roche Inc. Combination therapy and method for assessing resistance to treatment
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
WO2012050370A2 (ko) * 2010-10-15 2012-04-19 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
KR101330184B1 (ko) 2010-10-15 2013-11-15 성균관대학교산학협력단 감마-세크레타제 저해제를 유효성분으로 함유하는 류마티스성 관절염의 예방 또는 치료용 조성물
US20120114638A1 (en) 2010-11-08 2012-05-10 John Boylan Combination therapy
US20120184529A1 (en) 2011-01-14 2012-07-19 Demario Mark D Combination therapy
US20120225860A1 (en) 2011-03-02 2012-09-06 John Frederick Boylan Method for administration of a gamma secretase inhibitor
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯二氮呯酮化合物
AR087107A1 (es) 2011-07-27 2014-02-12 Lilly Co Eli Compuesto inhibidor de la señalizacion de la trayectoria notch
CN104822677A (zh) 2012-09-21 2015-08-05 百时美施贵宝公司 氟烷基-1,4-苯并二氮杂*酮化合物
US9242941B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
EP2897960B1 (en) 2012-09-21 2016-08-03 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds as notch inhibitors
CN104854094A (zh) 2012-09-21 2015-08-19 百时美施贵宝公司 氟烷基二苯并二氮杂*酮化合物
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥
WO2014047391A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
US9427442B2 (en) 2012-09-21 2016-08-30 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds
US9187434B2 (en) 2012-09-21 2015-11-17 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinones compounds
US9492469B2 (en) 2013-04-04 2016-11-15 Bristol-Myers Squibb Company Combination therapy for the treatment of proliferative diseases
EP2932966A1 (en) 2014-04-16 2015-10-21 Novartis AG Gamma secretase inhibitors for treating respiratory diseases
RU2707284C1 (ru) * 2015-10-30 2019-11-26 Пайплайн Терапьютикс, Инк. Дибензоазепиновые соединения и их применение для лечения ушных заболеваний и нарушений
CA3047096A1 (en) * 2016-12-16 2018-06-21 Pipeline Therapeutics, Inc. Methods of treating cochlear synaptopathy
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US11161825B2 (en) * 2017-08-15 2021-11-02 Bayer Aktiengesellschaft 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamides
CN118459594A (zh) 2018-06-01 2024-08-09 诺华股份有限公司 针对bcma的结合分子及其用途
CN119679936A (zh) 2019-06-24 2025-03-25 诺华股份有限公司 针对靶向b细胞成熟抗原的多特异性抗体的给药方案和组合疗法
CN116234898A (zh) * 2020-07-23 2023-06-06 普渡研究基金会 用于治疗肥胖症和代谢紊乱的Notch信号传导抑制剂
CA3229806A1 (en) * 2021-08-31 2023-03-09 Basf Se Herbicidal malonamides containing a condensed ring system
WO2024096358A1 (ko) 2022-11-04 2024-05-10 주식회사 엘지화학 홀로그램 기록 매체 및 이를 포함하는 광학 소자
CN116621721B (zh) * 2023-04-12 2025-03-18 珠海市柏瑞医药科技有限公司 一种壬二酰胺的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids
WO2001077086A1 (en) * 2000-04-11 2001-10-18 Dupont Pharmaceuticals Company SUBSTITUTED LACTAMS AS INHIBITORS OF Aβ PROTEIN PRODUCTION
GB0012671D0 (en) * 2000-05-24 2000-07-19 Merck Sharp & Dohme Therapeutic agents
MXPA05008172A (es) * 2003-02-04 2005-10-05 Hoffmann La Roche Derivados de malonamida como inhibidores gamma-secretasa.
ES2322652T3 (es) * 2003-09-09 2009-06-24 F. Hoffmann-La Roche Ag Derivados de malonamida bloqueantes de la actividad gamma-secretasa.

Also Published As

Publication number Publication date
ZA200601989B (en) 2007-05-30
IL173905A0 (en) 2006-07-05
JP2010229153A (ja) 2010-10-14
EP1711470A1 (en) 2006-10-18
CA2537440A1 (en) 2005-03-17
WO2005023772A1 (en) 2005-03-17
KR100834177B1 (ko) 2008-05-30
CR8264A (es) 2008-09-22
RS20060146A (sr) 2008-06-05
CO5660268A2 (es) 2006-07-31
KR20060054455A (ko) 2006-05-22
CN1875005A (zh) 2006-12-06
ECSP066414A (es) 2006-09-18
NZ545538A (en) 2008-12-24
PT1711470E (pt) 2009-05-21
UA83501C2 (uk) 2008-07-25
JP4571639B2 (ja) 2010-10-27
CA2537440C (en) 2012-07-10
TNSN06077A1 (fr) 2007-10-03
DE602004020680D1 (de) 2009-05-28
AU2004270361B2 (en) 2009-06-25
EA200600503A1 (ru) 2006-08-25
US7160875B2 (en) 2007-01-09
KR20070087233A (ko) 2007-08-27
AU2004270361A1 (en) 2005-03-17
EP1711470B1 (en) 2009-04-15
PL1711470T3 (pl) 2009-09-30
MA28034A1 (fr) 2006-07-03
SI1711470T1 (sl) 2009-08-31
BRPI0413533A (pt) 2006-10-10
KR100838852B1 (ko) 2008-06-16
CN100593539C (zh) 2010-03-10
ATE428698T1 (de) 2009-05-15
KR20070087690A (ko) 2007-08-28
HK1099014A1 (zh) 2007-08-03
ES2322652T3 (es) 2009-06-24
JP2007505063A (ja) 2007-03-08
MY141308A (en) 2010-04-16
NO20061047L (no) 2006-04-04
CY1109225T1 (el) 2014-07-02
IL173905A (en) 2011-05-31
EA009940B1 (ru) 2008-04-28
MXPA06002562A (es) 2006-06-20
DK1711470T3 (da) 2009-06-08
US20050054633A1 (en) 2005-03-10
AR045609A1 (es) 2005-11-02
HRP20090266T1 (en) 2009-06-30

Similar Documents

Publication Publication Date Title
TW200519092A (en) Malonamide derivatives
TW200634017A (en) Bi-and tricyclic substituted phenyl methanones
ATE11535T1 (de) N-heteroaryl-alkylendiamine, verfahren zu ihrer herstellung sowie ihre verwendung.
NO20085160L (no) Nye glucokinaseaktivatorer og deres anvendelse
CY1116865T1 (el) Παραγωγα υποκατεστημενης διβενζο-αζεπινης και βενζο-διαζεπινης χρησιμα ως αναστολεις της γαμμα-σεκρετασης
MX2009008465A (es) Nuevas 2-aminooxazolinas como ligandos de taar1.
TW200740760A (en) Malonamide derivatives
KR930005992A (ko) 루코트리엔 생합성 억제제
AR037418A1 (es) Derivados de benzotiazol
TW200635585A (en) Monocyclic substituted methanones
CA2324418A1 (en) Novel opiate compounds, methods of making and methods of use
NO20062517L (no) 2-cyanopyrrolidinkarboksamidforbindelse
MX2009011051A (es) Derivados de pirrolidina como antagonistas del receptor nk1/nk3 doble.
EA201071012A1 (ru) Производные азетидинов, способ их получения и применение их в терапии
DE69022744D1 (de) Piperidin und pyrrolidin derivate.
TW200510355A (en) Benzoxazepinone derivatives
NO20082226L (no) 6-heteroarylpyridoindolonderivater, deres fremstilling og terapeutisk anvendelse derav
NO20063330L (no) Amidderivater med en syklopropylaminokarbonylsubstituent som er nyttige som cytokininhibitorer
ATE90664T1 (de) 3,5-dihydroxy-6,8-nonadiensaeuren und -derivate als hypocholesterolemische mittel.
TR200100660T2 (tr) Piperidin türevleri.
DK0462933T3 (da) Hidtil ukendte N-benzyl-N1-phenyl og -phenylalkyl-thiourinstoffer
PL378343A1 (pl) Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny
EA201000666A1 (ru) Производные 5-замещенных индол-3-карбоновой кислоты, обладающие противовирусной активностью, способ их получения и применение
ATE71370T1 (de) 2-amino-5-hydroxy-4-pyrimidone.
NO885224D0 (no) FremgangsmŸte for fremstilling av 1,4-disubstituerte-piperidinylderivater.